Daiichi Sankyo R&D Division Oncology Function head, executive officer Koichi Akahane said: "There are no HER2-targeting treatment options currently available for patients with HER2-positive gastric cancer whose tumors
This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing
The round was oversubscribed. Adagene CEO Peter Luo said: "Adagene is built on a proprietary discovery engine that we have leveraged to discover highly differentiated portfolio of agonist
Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. It is based
RiVax has previously been granted orphan drug designation from the US Food and Drug Administration (FDA). The European Commission grants orphan designations for medicines that treat a life-threatening
The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as AI, aiming to shorten the period
The World Health Organization (WHO) estimates that the development of resistant bacteria could cause 10 million deaths per year by 2050 if no innovative treatment is developed. Deinove has
In the United States, Tasigna is now indicated for the treatment of adult and pediatric patients one year of age or older with newly diagnosed Ph+ CML-CP. Tasigna
Completion of the acquisition is subject to customary closing conditions, and is expected to close in the second quarter of 2018. Valchlor® is the first and only FDA-approved
The discovery collaboration is based on a new Regeneron publication in the New England Journal of Medicine identifying for the first time a variant in the HSD17B13 gene
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.